Xencor Presentations
Phase 1 study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients; Orlando, FL, June 1st, 2009 (CD30)
XmAb®5574: an Fc-Engineered Anti-CD19 Monoclonal Antibody with In Vitro and In Vivo Efficacy against Lymphoma and Leukemia; Chicago, IL, June 1st, 2008 (CD19)
American Association for Cancer Research (AACR) Annual Meeting;
San Diego, April 12-16, 2008 (CD19)
American Society of Hematology 49th Annual Meeting and Exposition;
Atlanta, GA, December 8-11, 2007 (CD30)
IBC Life Sciences’ 17th Annual Antibody Engineering Conference;
San Diego, December 2-6, 2007 (CD19)
7th International Symposium on Hodgkin Lymphoma;
Cologne, Germany, November 3-7, 2007 (CD30)
Life Sciences 2007;
Glasgow, UK, July 8-12, 2007 (Fc)
American Association for Cancer Research (AACR) Annual Meeting;
Los Angeles, April 14-18, 2007 (Fc)
American Association for Cancer Research (AACR) Annual Meeting;
Los Angeles, April 14-18, 2007 (CD19)
American College of Rheumatology (ACR): Innovative Therapies in Autoimmune Diseases;
Arlington, VA, March 2-4, 2007
IBC Protein Engineering for Biotherapeutics Conference;
San Diego, December 12-14, 2006 (Fc)
IBC Protein Engineering for Biotherapeutics Conference;
San Diego, December 12-14, 2006 (ImmunoFilter technology)
American Society of Hematology (ASH) Annual Meeting 2005;
Atlanta, GA; December 10-13, 2005